Correlation Engine 2.0
Clear Search sequence regions

  • avanafil (8)
  • humans (1)
  • isoform (1)
  • organ (1)
  • patients (5)
  • phase (1)
  • prostate (2)
  • pyrimidines (2)
  • sexual function (1)
  • sildenafil (8)
  • Sizes of these terms reflect their relevance to your search.

    Phosphodiesterase type 5 inhibitors represent the standard treatment of erectile dysfunction after nerve-sparing prostatectomy. Avanafil is a second-generation phosphodiesterase type 5 inhibitor with a high selectivity for phosphodiesterase type 5 isoform. To date, there are no studies comparing the outcomes of avanafil versus sildenafil in this scenario. In this study, we evaluated the efficacy and safety of avanafil versus sildenafil as a drug for post-prostatectomy rehabilitation. Overall, 160 patients submitted to robot-assisted nerve-sparing prostatectomy for localized prostate cancer at three hospitals were enrolled for the present study. After 6 months of treatment, patients in the two groups showed no significantly different sexual function scores, except for the Erection Hardness Score and Sexual Encounter Profile-Q2 that were higher in the Sildenafil group. Adverse events in the Avanafil group occurred in four (5%) patients and in 16 (20%) patients in the Sildenafil group. According to our experience, in patients undergoing nerve-sparing prostatectomy, penile rehabilitation with avanafil compared to sildenafil showed a lower ability to produce a valid erection in the initial phase of sexual intercourse, a difference that disappears in the continuation of the same. Avanafil showed a greater tolerance profile with a lower rate of AEs and discontinuation of therapy due to AEs.


    Pier Andrea Della Camera, Riccardo Tellini, Gianmartin Cito, Giulia Rastrelli, Mario Maggi, Tommaso Chini, Cosimo De Nunzio, Vincenzo Maria Altieri, Sergio Serni, Mauro Gacci, Alessandro Natali. Efficacy and safety of avanafil 200 mg versus sildenafil 100 mg in the treatment of erectile dysfunction after robot-assisted unilateral nerve-sparing prostatectomy: A prospective multicentre study. Urologia. 2020 Feb;87(1):23-28

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 31441379

    View Full Text